[Asia Economy Reporter Seo So-jeong] The Ministry of Food and Drug Safety (Director Kim Kang-lip) approved the Phase 2 clinical trial of ImmuneMed's novel coronavirus disease (COVID-19) antibody treatment 'hzVSF-v13' on the 7th.


This clinical trial is a Phase 2 study to verify the efficacy and safety of the treatment in patients with moderate to severe COVID-19.


hzVSF-v13 is a component being developed as an influenza treatment, and a Phase 1 clinical trial was conducted on healthy individuals to evaluate safety during its development.


The treatment mechanism involves the drug binding to cellular structures related to viral infection, thereby inhibiting viral replication.


The Ministry of Food and Drug Safety stated, "Considering the high public interest in the development of COVID-19 treatments and vaccines, we will promptly provide information on the status of clinical trials for products under development."


Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ① "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

Currently, there are a total of 34 approved clinical trials related to COVID-19 in Korea, of which 26 (21 treatments and 5 vaccines) are ongoing.


한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing